

THE 1st SHMUNIS CANCER CONFERENCE

MARCH 9, 2023 AND MUSEUM OF THE JEWISH PEOPLE TEL AVIV UNIVERSITY

08:30 – 9:00

Gathering

09:00 - 09:15

Welcome and Greetings

Dan Peer, Vice President for Research and

Development, TAU

Abdussalam Azem, Dean, George S. Wise

Faculty of Life Sciences, TAU

Anat Herskovits, Head, The Shmunis School of Biomedicine and Cancer

Research, TAU

Mr. Vlad Shmunis, USA

Entrepreneur and Philanthropist

SESSION 1: THE TUMOR MICROENVIRONMENT Chair: Adit Ben-Baruch TALL

09:15 – 09:35 **Isaac P. Witz**, TAU

Awardee, Career Achievement in

Cancer Research Award

09:35 – 10:00 **Lior Mayo**, TAU

Shutting down glioblastoma:

How astrocytes contribute to tumor

progression

10:00 – 10:35 **Michael Karin**, UCSD

Control of pancreatic cancer metabolism

and clinical outcome by collagen

turnover

10:35 – 11:00 Coffee Break

Conference Chair: Adit Ben-Baruch aditbb@tauex.tau.ac.il

Conference Coordinator: Tal Oded

taloded@tauex.tau.ac.il

Free Registration Link:

HTTPS://EN-LIFESCI.TAU.AC.IL/FORM_SHMUNIS

SESSION 2: CANCER MECHANISMS Chair: Martin Kupiec, TAU

11:00 – 11:35 Sylvia K. Plevritis, Stanford

Spatial biology of cancer reveals

cell-cell colocalizations and interactions

associated with progression

11:35 – 12:05 Flash Talks by Graduate Students, TAU

12:05 – 12:30 **Marcelo Ehrlich**, TAU

Identifying, exploiting and enhancing

the susceptibilities of cancer cells to

oncolytic viruses

12:30 – 13:05 Steven Artandi, Stanford

Role of telomerase in stem cells and

cancer

13:05 – 14:00 Break

SESSION 3: THE RESEARCH-CLINIC INTERFACE

14:00 – 14:25	Dan Peer , TAU

Therapeutic genome editing in cancer

14:25 – 14:50 **Vered Padler-Karavani**, TAU

Targeting the sweet spots of cancer

14:50 – 15:15 **Itai Benhar**, TAU

Antibody-targeted lipid nanoparticle mediated inhibition of the GPCR RXFP1 signaling pathway as a therapeutic

approach for ovarian cancer

15:15 – 15:50 Maria Grazia Roncarolo, Stanford

Regulatory T cell therapy: Progress and

hurdles

15:50 – 16:25 **Carlos Arteaga**, UT Southwestern

Drug resistance in ER+ breast cancer

16:25 – 16:30 Meeting Closure







